Jamjoom Pharma nine-month net profit rises 5.1% to $110.5m
Revenue growth and gross margin expansion drove the Saudi pharmaceutical manufacturer's earnings in the first nine months of 2026.
Jamjoom Pharma reported net profit of $110.5 million for the nine months ended September 2026, an increase of 5.1 percent on the corresponding period of the prior year. The Saudi pharmaceutical manufacturer disclosed the result in a filing, attributing the gain to revenue growth and gross margin expansion.
Revenue growth and production efficiencies#
The company stated that revenue increased during the period, supported by volume gains across its product portfolio. Gross margin widened as a result of production efficiencies implemented at its manufacturing facilities and a favorable shift in product mix. The filing did not quantify the revenue figure or specify which product categories contributed most to the mix improvement. Jamjoom Pharma operates manufacturing sites in Saudi Arabia producing generic pharmaceuticals and over-the-counter medicines for domestic and regional markets.
Geographic mix contribution#
The company reported that its geographic sales mix also contributed to the margin expansion, with higher-margin markets accounting for a larger share of total revenue in the nine-month period. The filing did not identify which markets delivered the improved contribution or provide a breakdown of sales by region. Jamjoom Pharma exports to markets across the Middle East and North Africa, in addition to its home market sales in Saudi Arabia.
Earnings in Saudi riyals#
Net profit for the nine months reached SAR 416.05 million, the company stated. The prior-year comparative figure was not disclosed in the available filing. Jamjoom Pharma is listed on the Saudi Exchange and reports its financial results in Saudi riyals, with the dollar equivalent calculated at the prevailing exchange rate. The company has not announced a date for the release of its full-year 2026 results.
Production and portfolio strategy#
The filing attributed the production efficiencies to process improvements and capacity utilization gains at the company's manufacturing operations. Jamjoom Pharma manufactures solid oral dosage forms, liquids and topical preparations across therapeutic categories including cardiovascular, gastrointestinal and anti-infective medicines. The favorable product mix reflected higher sales of products with stronger gross margins, the company stated, without naming specific products or therapeutic areas that drove the shift.
Sources1 source across 1 domain
- forbesmiddleeast.comForbes Middle EastJamjoom Pharma net profit of $110.5 million for nine months ended September 2026, up 5.1%, driven by revenue growth, gross margin expansion from production efficiencies and favorable product and geographic mix
Each source above carries the claim it supports. Links open the publisher's own page; their text is not reproduced here beyond what the claim requires, and their rights remain theirs.
Equity Arabia is published by Arabian Media Network. Pieces are produced by the Primary Debt Desk with AI-assisted synthesis of the cited sources and automated verification against the network's editorial policy. Every piece carries a desk rather than a reporter. Corrections are recorded on the piece and on the corrections page.